1-[3-(2-chloropyridin-4-yl)-[2,6]naphthyridin-1-yl]piperidine-4-carboxylic acid isobutylamide | 1071130-67-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-[3-(2-chloropyridin-4-yl)-[2,6]naphthyridin-1-yl]piperidine-4-carboxylic acid isobutylamide
• 英文别名: 1-[3-(2-Chloropyridin-4-yl)-[2,6]naphthyridin-1-yl]-piperidine-4-carboxylic acid isobutyl-amide；1-[3-(2-chloropyridin-4-yl)-2,6-naphthyridin-1-yl]-N-(2-methylpropyl)piperidine-4-carboxamide
• CAS: 1071130-67-0
• 化学式: C₂₃H₂₆ClN₅O
• 分子量: 423.945
• InChiKey: KFJVITIDUOEOGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  71
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-[3-(2-chloropyridin-4-yl)-[2,6]naphthyridin-1-yl]piperidine-4-carboxylic acid isobutylamide 、 正丁胺 在 palladium diacetate 、 JosiPhos sodium t-butanolate 作用下， 以 乙二醇二甲醚 为溶剂， 反应 9.0h， 以71%的产率得到1-[3-(2-butylaminopyridin-4-yl)-[2,6]naphthyridin-1-yl]piperidine-4-carboxylic acid isobutylamide
  参考文献：
  名称：

  WO2008/122615

  摘要：

  公开号：
• 作为产物：
  描述：

  1-[3-(2-chloropyridin-4-yl)[2,6]naphthyridin-1-yl]piperidine-4-carboxylic acid 、 异丁胺 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 1-羟基苯并三唑 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 1-[3-(2-chloropyridin-4-yl)-[2,6]naphthyridin-1-yl]piperidine-4-carboxylic acid isobutylamide
  参考文献：
  名称：

  Identification of Orally Available Naphthyridine Protein Kinase D Inhibitors

  摘要：

  A novel 2,6-naphthyridine was identified by high throughput screen (HTS) as a dual protein kinase C/D (PKC/PKD) inhibitor. PKD inhibition in the heart was proposed as a potential antihypertrophic mechanism with application as a heart failure therapy. As PKC was previously identified as the immediate upstream activator of PKD, PKD vs PKC selectivity was essential to understand the effect of PKD inhibition in models of cardiac hypertrophy and heart failure. The present study describes the modification of the HTS hit to a series of prototype pan-PKD inhibitors with routine 1000-fold PKD vs PKC selectivity. Example compounds inhibited PKD activity in vitro, in cells, and in vivo following oral administration. Their effects on heart morphology and function are discussed herein.

  DOI：

  10.1021/jm100075z

文献信息

• ORGANIC COMPOUNDS
  申请人：Dobler Markus Rolf

  公开号：US20120142685A1

  公开（公告）日：2012-06-07

  The present invention provides a compound formula I: (formula I) said compound is inhibitor of selective subset of kinases belonging to the AGC or calmodulin kinase family, such as for example MARK1/2/3, PKD-1/2/3, PKN-1/2, CDK-9, CaMKII, ROCK-I/II, inhibitors of histone deacetylase (HDAC) phosphorylation, or inhibitors of other kinases. Finally, the present invention also provides a pharmaceutical composition.

  本发明提供了一个化合物公式I：（公式I），该化合物是AGC或钙调素激酶家族的选择性亚集的抑制剂，例如MARK1/2/3，PKD-1/2/3，PKN-1/2，CDK-9，CaMKII，ROCK-I/II，组蛋白去乙酰化酶（HDAC）磷酸化抑制剂，或其他激酶的抑制剂。最后，本发明还提供了一种制药组合物。
• [2,6]NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS
  申请人：Novartis AG

  公开号：EP2144909B1

  公开（公告）日：2011-03-23
• [2, 6]NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS
  申请人：Novartis AG

  公开号：EP2144909A1

  公开（公告）日：2010-01-20
• [EN] [2, 6] NAPHTHYRIDINES USEFUL AS PROTEIN KINASE INHIBITORS<br/>[FR] [2,6]NAPHTHYRIDINES UTILES EN TANT QU'INHIBITEURS DES PROTEINES KINASES
  申请人：NOVARTIS AG

  公开号：WO2008122615A1

  公开（公告）日：2008-10-16

  [EN] The present invention provides a compound of formula I: (formula I) said compound is inhibitor of selective subset of kinases belonging to the AGC or calmodulin kinase family, such as for example MARK1/2/3, PKD-1/2/3, PKN-1/2, CDK-9, CaMKII, ROCK-I/II, inhibitors of histone deacetylase (HDAC) phosphorylation, or inhibitors of other kinases. Finally, the present invention also provides a pharmaceutical composition.
  [FR] L'invention concerne un composés de formule I : (formule I), utile en tant qu'inhibiteur d'un sous-ensemble sélectif de kinases appartenant à la famille des kinases AGC ou calmoduline, telles que MARK1/2/3, PKD-1/2/3, PKN-1/2, CDK-9, CaMKII, ROCK-I/II, inhibiteurs de la phosphorylation d'histone désacétylase (HDAC) ou inhibiteurs d'autres kinases. L'invention concerne également une composition pharmaceutique associée.
• WO2008/122615
  申请人：——

  公开号：——

  公开（公告）日：——